Videos

Considerations for treatment selection for chemotherapy-induced neutropenia.

General considerations surrounding the risk of chemotherapy-induced neutropenia in solid tumors.

Larry D. Anderson, Jr, MD, PhD, discusses the rationale behind using chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma, data from the KarMMa trial, and other trials investigating this treatment.

Considering a patient’s relapse and potential response to therapy, Daniel O. Persky, MD, looks forward to the future use of novel therapies in diffuse large B-cell lymphoma.

Expert insight on the GO29365 trial, which informs selection of polatuzumab + bendamustine and rituximab in patients with relapsed/refractory DLBCL.

Daniel O. Persky, MD, reflects on a patient’s relapse with diffuse large B-cell lymphoma and the rationale behind treatment with polatuzumab + BR.

A review of frontline treatment options for DLBCL informed by comprehensive patient workup and the efficacy of available therapies.

Expert hematologist/oncologist Daniel O. Persky, MD, reviews the case of a 73-year-old woman who is diagnosed with and treated for DLBCL, later to relapse and require novel therapy.

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center discusses the results of the phase 2 study of tislelizumab in patients with unresectable hepatocellular carcinoma.

Nizar M. Tannir, MD, FACP, discusses why telaglenastat in combination with cabozantinib did not improve efficacy in compared with cabozantinib alone in patients with metastatic renal cell carcinoma.

In this first video of the series, Neeraj Agarwal, MD, of the Huntsman Cancer Institute of the University of Utah explains the role of imaging and genomic testing in the diagnosis and treatment of prostate cancer.

John Mascarenhas, MD, and Ruben Mesa, MD, share insights on the role of IRAK signaling on the disease biology of myelofibrosis.

Advice regarding patient selection for sacituzumab govitecan and the management of treatment-related adverse events.

Recommendations regarding how to best integrate newer therapies, including antibody-drug conjugates, into treatment plans for patients with advanced urothelial carcinoma.

Hematology/oncology experts review the role of JAK2 allele burden in patients and its effect on treatment outcomes for myelofibrosis.

Tycel Jovelle Phillips, MD, discusses the design of a phase 1 study looking at venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma.

Joel Neal, MD, PhD, and Alexander I Spira, MD, PhD, FACP, review amivantamab and poziotinib as other treatment options for EGFR Exon 20 Insertion+ NSCLC.

An explanation of the EXCLAIM Trial and the mechanism of action, clinical development, and the overall clinical development program of mobocertinib.

Lori Wirth, MD, discusses the future of selpercatinib in RET-altered thyroid cancers. 

Christopher R. Flowers, MD, discusses the current therapies used for patients with relapsed/refractory diffuse large B-cell lymphoma and goes into specifics of the L-MIND trial after the long-term follow-up.

Haris Ali, MD, a hematology oncologist at the City of Hope Comprehensive Cancer Center, discusses common myeloproliferative neoplasms driver mutations. 

The rationale for treating patients with advanced urothelial carcinoma with sacituzumab govitecan, a novel antibody-drug conjugate now approved that targets Trop-2.

Ruben Mesa, MD, and John Mascarenhas, MD, discuss whether therapies with a clinically meaningful impact on myelofibrosis may have a survival advantage for patients.

Expert hematologist/oncologists comment on the value of reducing fibrosis as a potential goal of therapy when treating patients with myelofibrosis.

Reactions to the availability of antibody-drug conjugates as later-line therapy for patients with metastatic urothelial carcinoma, and potential considerations for adopting enfortumab vedotin into clinical practice.

Peter Riedell, MD, an assistant professor of medicine at University of Chicago Medicine, discusses outcomes for mantle cell lymphoma patients and the impact of the timing of relapse on overall survival after autologous stem cell transplantation.

Bishoy M. Faltas, MD, Fellow, Hematology/Oncology, Weill Cornell Medical College, discusses genomic testing in urothelial cancer.

Dr Evan Y. Yu shares sequencing strategies for LuPSMA radioligand therapy in patients with PSMA-positive mCRPC.

Evan Y. Yu, MD, reviews the phase 2 TheraP trial evaluating PSA response in patients with PSMA-positive mCRPC who received LuPSMA therapy vs cabazitaxel.

An expert in prostate cancer comments on patient response to 177Lu-PSMA-617 therapy, particularly for patients with mCRPC who have liver metastases.